HomeCompareFMEDX vs NNN

FMEDX vs NNN: Dividend Comparison 2026

FMEDX yields 17.73% · NNN yields 5.66%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FMEDX wins by $38.0K in total portfolio value
10 years
FMEDX
FMEDX
● Live price
17.73%
Share price
$11.28
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.5K
Annual income
$5,247.63
Full FMEDX calculator →
NNN
NNN REIT Inc.
● Live price
5.66%
Share price
$42.03
Annual div
$2.38
5Y div CAGR
8.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.5K
Annual income
$2,622.67
Full NNN calculator →

Portfolio growth — FMEDX vs NNN

📍 FMEDX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFMEDXNNN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FMEDX + NNN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FMEDX pays
NNN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FMEDX
Annual income on $10K today (after 15% tax)
$1,507.09/yr
After 10yr DRIP, annual income (after tax)
$4,460.49/yr
NNN
Annual income on $10K today (after 15% tax)
$481.32/yr
After 10yr DRIP, annual income (after tax)
$2,229.27/yr
At 15% tax rate, FMEDX beats the other by $2,231.22/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FMEDX + NNN for your $10,000?

FMEDX: 50%NNN: 50%
100% NNN50/50100% FMEDX
Portfolio after 10yr
$44.5K
Annual income
$3,935.15/yr
Blended yield
8.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NNN right now

FMEDX
No analyst data
NNN
Analyst Ratings
10
Buy
15
Hold
4
Sell
Consensus: Hold
Price Target
$44.93
+6.9% upside vs current
Range: $43.00 — $48.50
Altman Z
1.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FMEDX buys
0
NNN buys
0
No recent congressional trades found for FMEDX or NNN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFMEDXNNN
Forward yield17.73%5.66%
Annual dividend / share$2.00$2.38
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%8.6%
Portfolio after 10y$63.5K$25.5K
Annual income after 10y$5,247.63$2,622.67
Total dividends collected$33.8K$13.7K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: FMEDX vs NNN ($10,000, DRIP)

YearFMEDX PortfolioFMEDX Income/yrNNN PortfolioNNN Income/yrGap
1← crossover$12,473$1,773.05$10,735$614.96+$1.7KFMEDX
2$15,413$2,066.85$11,572$708.43+$3.8KFMEDX
3$18,879$2,386.94$12,531$819.53+$6.3KFMEDX
4$22,933$2,732.41$13,633$952.29+$9.3KFMEDX
5$27,640$3,102.01$14,909$1,111.84+$12.7KFMEDX
6$33,069$3,494.15$16,392$1,304.77+$16.7KFMEDX
7$39,291$3,906.97$18,129$1,539.52+$21.2KFMEDX
8$46,380$4,338.36$20,173$1,827.08+$26.2KFMEDX
9$54,412$4,786.05$22,597$2,181.81+$31.8KFMEDX
10$63,469$5,247.63$25,491$2,622.67+$38.0KFMEDX

FMEDX vs NNN: Complete Analysis 2026

FMEDXStock

Normally the fund invests at least 80% of assets in securities of disruptive medicine companies. Normally it invests primarily in equity securities. Companies within the disruptive medicine theme include but are not limited to those companies that, in the Adviser's opinion, are engaged in robotic surgery, gene therapy, genomics, rare diseases, medical devices and equipment, immunotherapy, technology-based health care platforms, and consumer wellness. The fund is non-diversified.

Full FMEDX Calculator →

NNNREIT

National Retail Properties invests primarily in high-quality retail properties subject generally to long-term, net leases. As of September 30, 2020, the company owned 3,114 properties in 48 states with a gross leasable area of approximately 32.4 million square feet and with a weighted average remaining lease term of 10.7 years.

Full NNN Calculator →
📬

Get this FMEDX vs NNN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FMEDX vs SCHDFMEDX vs JEPIFMEDX vs OFMEDX vs KOFMEDX vs MAINFMEDX vs ADCFMEDX vs EPRTFMEDX vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.